Invention Grant
US09580476B2 Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
有权
基于腺病毒载体的呼吸道合胞病毒（RSV）疫苗
- Patent Title: Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
- Patent Title (中): 基于腺病毒载体的呼吸道合胞病毒（RSV）疫苗
-
Application No.: US14349735Application Date: 2012-10-05
-
Publication No.: US09580476B2Publication Date: 2017-02-28
- Inventor: Douglas E. Brough , Jason G. D. Gall , Duncan McVey
- Applicant: GenVec, Inc.
- Applicant Address: US MD Gaithersburg
- Assignee: GenVec, Inc.
- Current Assignee: GenVec, Inc.
- Current Assignee Address: US MD Gaithersburg
- Agency: Leydig, Voit & Mayer, Ltd.
- International Application: PCT/US2012/059043 WO 20121005
- International Announcement: WO2013/052859 WO 20130411
- Main IPC: C07K14/005
- IPC: C07K14/005 ; C12N15/86
Abstract:
The invention provides an adenovirus or adenoviral vector characterized by comprising a nucleic acid sequence encoding one or more Respiratory Syncytial Virus (RSV) antigens and one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein, as well as a method of inducing an immune response against RSV in a mammal by administering the adenovirus or adenoviral vector to the mammal.
Public/Granted literature
- US20140271711A1 ADENOVIRAL VECTOR-BASED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE Public/Granted day:2014-09-18
Information query
